Unicycive Therapeutics, Inc
  • About
    • Our Story
    • Our Focus
    • Our Team
    • Board of Directors
  • Our Science
    • Our Approach
    • Pipeline
    • Oxylanthanum Carbonate (OLC)
    • UNI-494
    • Publications & Press
  • Investors
  • Contact
    • Careers

News

Investors

Investors

  • Overview
  • News
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Financial Results
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • Contacts
    • FAQ
    • Email Alerts
Aug 14, 2023 5:36pm EDT

Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 20, 2023 7:03am EDT

Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference

Jul 18, 2023 7:03am EDT

Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology

Jun 29, 2023 5:04pm EDT

Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program

Jun 16, 2023 7:38am EDT

Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

May 16, 2023 8:29am EDT

Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update

Apr 24, 2023 7:00am EDT

Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress

Mar 31, 2023 7:00am EDT

Unicycive Announces Full Year 2022 Financial Results and Provides Business Update

Mar 06, 2023 7:00am EST

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb

Feb 27, 2023 7:00am EST

Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Unicycive Theraputics, Inc

About
Our story
Our focus
Our team
Boards of Directors

Our Science
Our Approach
Therapeutic Pipeline
OLC
UNI-494
Publications & Press

Investors

Contact
Careers

4300 El Camino Real, Suite #210
Los Altos, CA 94022
+1 (650) 351-4495
info@unicycive.com

  • LinkedIn
  • YouTube
  • Facebook
  • Instagram
  • Twitter

Copyright © 2025 Unicycive

Legal Notices and Terms of Use Privacy Policy Ad and Cookie Policy